Skip to main content
Erschienen in: Clinical & Experimental Metastasis 8/2013

01.12.2013 | Research Paper

Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs

verfasst von: Lutfiye Demir, Seyran Yigit, Hulya Ellidokuz, Cigdem Erten, Isil Somali, Yuksel Kucukzeybek, Ahmet Alacacioglu, Suna Cokmert, Alper Can, Murat Akyol, Ahmet Dirican, Vedat Bayoglu, Aysegul Akder Sari, Mustafa Oktay Tarhan

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to investigate the prognostic and predictive effect of FOXP3+ Tregs together with clinicopathologic factors in locally advanced breast cancer (LABC) patients. The medical records of 101 LABC patients who received neoadjuvant chemotherapy (NAC) between 2005 and 2012 were evaluated retrospectively. The density of intratumoral FOXP3+ lymphocytes in paraffin-embedded tissues was assessed by immunohistochemical analyses in appropriate cases. The relationship with clinicopathologic features, prognosis and chemotherapy response was investigated. HR(–) and HER2(+) tumors tended to have higher pre-chemotherapy Tregs than HR(+) tumors, and significantly higher pathologic complete response (PCR) rates were observed in these patients. Treg decline after NAC was associated with better pathological response rates. Lower intratumoral infiltration of FOXP3+ Tregs after NAC (<3.4/HPF) was significantly associated with higher PCR rates for breast, and close to the significance limit for total (or both for breast and axillary) PCR rates (PCR for breast: 25 vs. 2.9 % for low vs. high Treg, p = 0.001; PCR for breast + axillary tissue: 13.9 vs. 0 %, p = 0.05). Despite better PCR rates, patients with high intratumoral Treg infiltrates (≥11.5/HPF) before chemotherapy had significantly shorter overall survival than patients with low Treg infiltrates (<11.5/HPF). Cox multivariate regression analyses demonstrated that the density of Treg infiltration before chemotherapy was the strongest predictor for survival. This study established the predictive and prognostic effect of intratumoral FOXP3+ Tregs in LABC patients. To predict clinical outcome, evaluation of FOXP3+ Tregs in tumoral tissues before and after NAC should be considered for these high-risk patients.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. Cancer J Clin 60:277–300CrossRef Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. Cancer J Clin 60:277–300CrossRef
2.
Zurück zum Zitat Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF (2009) Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol 35:113–122PubMedCrossRef Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF (2009) Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol 35:113–122PubMedCrossRef
3.
Zurück zum Zitat Alizadeh AA, Ross DT, Perou CM, van de Rjin M (2001) Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 195:41–52PubMedCrossRef Alizadeh AA, Ross DT, Perou CM, van de Rjin M (2001) Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 195:41–52PubMedCrossRef
4.
Zurück zum Zitat Kuere HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor an axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469 Kuere HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor an axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469
5.
Zurück zum Zitat von Minckwitz G, Loibl S, Maisch A, Untch M (2011) Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. Breast 20:S142–S145CrossRef von Minckwitz G, Loibl S, Maisch A, Untch M (2011) Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. Breast 20:S142–S145CrossRef
6.
Zurück zum Zitat Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD, Sánchez-Rovira P (2008) Tumor molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locallyadvanced breast cancer. Clin Transl Oncol 10:646PubMedCrossRef Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD, Sánchez-Rovira P (2008) Tumor molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locallyadvanced breast cancer. Clin Transl Oncol 10:646PubMedCrossRef
7.
Zurück zum Zitat Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236–4244PubMedCrossRef Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236–4244PubMedCrossRef
8.
Zurück zum Zitat Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328–7333PubMedCrossRef Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328–7333PubMedCrossRef
9.
Zurück zum Zitat Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ (2007) Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7:203PubMedCrossRef Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ (2007) Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7:203PubMedCrossRef
10.
Zurück zum Zitat Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS (2005) The relationship between tumor T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92:651–654PubMedCrossRef Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS (2005) The relationship between tumor T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92:651–654PubMedCrossRef
11.
Zurück zum Zitat Takagi S, Chen K, Schwarz R, Iwatsuki S, Herberman RB, Whiteside TL (1989) Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer 63:102–111PubMedCrossRef Takagi S, Chen K, Schwarz R, Iwatsuki S, Herberman RB, Whiteside TL (1989) Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer 63:102–111PubMedCrossRef
12.
Zurück zum Zitat Oble DA, Loewe R, Yu P, Mihm MC Jr (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3PubMed Oble DA, Loewe R, Yu P, Mihm MC Jr (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3PubMed
13.
Zurück zum Zitat DeNardo DG, Coussens LM (2007) Inflammation and breast cancer: balancing immune response-crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9:212PubMedCrossRef DeNardo DG, Coussens LM (2007) Inflammation and breast cancer: balancing immune response-crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9:212PubMedCrossRef
14.
Zurück zum Zitat Rakha EA, Aleskandarany M, El Sayed ME, Blamey RW, Elston CW, Ellis IO, Lee AH (2009) The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45:1780–1787PubMedCrossRef Rakha EA, Aleskandarany M, El Sayed ME, Blamey RW, Elston CW, Ellis IO, Lee AH (2009) The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45:1780–1787PubMedCrossRef
15.
Zurück zum Zitat Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S (2008) FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 8:57PubMedCrossRef Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S (2008) FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 8:57PubMedCrossRef
16.
Zurück zum Zitat Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR (2011) Tumour-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949–1955PubMedCrossRef Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR (2011) Tumour-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949–1955PubMedCrossRef
17.
Zurück zum Zitat Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO (2012) CD8+ lymphocyte infiltration is an independent favourable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14:R48PubMedCrossRef Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO (2012) CD8+ lymphocyte infiltration is an independent favourable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14:R48PubMedCrossRef
18.
Zurück zum Zitat Lim KH, Telisinghe PU, Abdullah MS, Ramasamy R (2010) Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun 10:3PubMed Lim KH, Telisinghe PU, Abdullah MS, Ramasamy R (2010) Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun 10:3PubMed
19.
Zurück zum Zitat Hori S, Monura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor FoxP3. Science 299:1057–1061PubMedCrossRef Hori S, Monura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor FoxP3. Science 299:1057–1061PubMedCrossRef
20.
Zurück zum Zitat Bohling SD, Allison KH (2008) Immunosuppressive regulatory Tcells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol 21:1527–1532PubMedCrossRef Bohling SD, Allison KH (2008) Immunosuppressive regulatory Tcells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol 21:1527–1532PubMedCrossRef
21.
Zurück zum Zitat Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, Yin D, Gu F, Yao Z, Fu L (2011) CD8(+) cytotoxic T cell and FOXP3(+) regulatory Tcell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130:645–655PubMedCrossRef Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, Yin D, Gu F, Yao Z, Fu L (2011) CD8(+) cytotoxic T cell and FOXP3(+) regulatory Tcell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130:645–655PubMedCrossRef
22.
Zurück zum Zitat Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105–113PubMedCrossRef Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105–113PubMedCrossRef
23.
Zurück zum Zitat Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F (2008) Pathologic complete response to neoadjuvant chemotherapy of breast cancer is associated with the disappearence of tumor-infiltrating FOXP3+ regulatory Tcells. Clin Cancer Res 14:2413–2420PubMedCrossRef Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F (2008) Pathologic complete response to neoadjuvant chemotherapy of breast cancer is associated with the disappearence of tumor-infiltrating FOXP3+ regulatory Tcells. Clin Cancer Res 14:2413–2420PubMedCrossRef
24.
Zurück zum Zitat Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F (2011) In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 224:389–400PubMedCrossRef Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F (2011) In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 224:389–400PubMedCrossRef
25.
Zurück zum Zitat Liu F, Li Y, Ren M, Zhang X, Guo X, Lang R, Gu F, Fu L (2012) Peritumoral FOXP3+ regulatory Tcell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat 135:459–467PubMedCrossRef Liu F, Li Y, Ren M, Zhang X, Guo X, Lang R, Gu F, Fu L (2012) Peritumoral FOXP3+ regulatory Tcell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat 135:459–467PubMedCrossRef
26.
Zurück zum Zitat Cancer staging manual (2010) AJCC, 7th edn. Springer, Chicago Cancer staging manual (2010) AJCC, 7th edn. Springer, Chicago
27.
Zurück zum Zitat Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124:966–978PubMed Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124:966–978PubMed
28.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
29.
Zurück zum Zitat Lee S, Cho EY, Park YH, Ahn JS, Im YH (2013) Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol 52:73–81PubMedCrossRef Lee S, Cho EY, Park YH, Ahn JS, Im YH (2013) Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol 52:73–81PubMedCrossRef
30.
Zurück zum Zitat Gülben K, Berberoğlu U, Cengiz A, Altinyollar H (2007) Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer. World J Surg 31:1724–1730PubMedCrossRef Gülben K, Berberoğlu U, Cengiz A, Altinyollar H (2007) Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer. World J Surg 31:1724–1730PubMedCrossRef
31.
Zurück zum Zitat Smoot RL, Koch CA, Degnim AC, Sterioff S, Donohue JH, Grant CS, Barnes SA, Gullerud RE, Hobday TJ, Farley DR (2006) A single-center experience with inflammatory breast cancer, 1985–2003. Arch Surg 141:567–573PubMedCrossRef Smoot RL, Koch CA, Degnim AC, Sterioff S, Donohue JH, Grant CS, Barnes SA, Gullerud RE, Hobday TJ, Farley DR (2006) A single-center experience with inflammatory breast cancer, 1985–2003. Arch Surg 141:567–573PubMedCrossRef
32.
Zurück zum Zitat Precht LM, Lowe KA, Atwood M, Beatty JD (2010) Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 16:362–368PubMed Precht LM, Lowe KA, Atwood M, Beatty JD (2010) Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 16:362–368PubMed
33.
Zurück zum Zitat Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT (2010) The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 17:2411–2418PubMedCrossRef Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT (2010) The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 17:2411–2418PubMedCrossRef
34.
Zurück zum Zitat Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A (2008) Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 19:465–472PubMedCrossRef Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A (2008) Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 19:465–472PubMedCrossRef
35.
Zurück zum Zitat Darb-Esfahani S, Loibl S, Muller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G (2009) Identification of biology-based breast cancer types with distinct predicitive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 11:R69PubMedCrossRef Darb-Esfahani S, Loibl S, Muller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G (2009) Identification of biology-based breast cancer types with distinct predicitive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 11:R69PubMedCrossRef
36.
Zurück zum Zitat Esserman LJ, Berry DA, Cheang MCU et al (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALBG 150007/150012;ACRIN 6657). Breast Cancer Res Treat 132:1049–1062PubMedCrossRef Esserman LJ, Berry DA, Cheang MCU et al (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALBG 150007/150012;ACRIN 6657). Breast Cancer Res Treat 132:1049–1062PubMedCrossRef
37.
Zurück zum Zitat Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48:3342–3354PubMedCrossRef Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48:3342–3354PubMedCrossRef
38.
Zurück zum Zitat West NR, Kost SE, Martin SD, Milne K, deLeeuw RJ, Nelson BH, Watson PH (2013) Tumour-infiltrating FOXP3+ lymphocytes are asociated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 108:155–162PubMedCrossRef West NR, Kost SE, Martin SD, Milne K, deLeeuw RJ, Nelson BH, Watson PH (2013) Tumour-infiltrating FOXP3+ lymphocytes are asociated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 108:155–162PubMedCrossRef
39.
Zurück zum Zitat Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM (2009) Paclitaxel reduces regulatory Tcell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 58:615–628PubMedCrossRef Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM (2009) Paclitaxel reduces regulatory Tcell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 58:615–628PubMedCrossRef
40.
Zurück zum Zitat Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, Shimoda M, Kagara N, Maruyama N, Kim SJ, Noguchi S (2012) Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat 136:107–116PubMedCrossRef Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, Shimoda M, Kagara N, Maruyama N, Kim SJ, Noguchi S (2012) Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat 136:107–116PubMedCrossRef
41.
Zurück zum Zitat de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, Speetjens FM, Smit VT, Liefers GJ, van de Velde CJ, Kuppen PJ (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16:1272–1280PubMedCrossRef de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, Speetjens FM, Smit VT, Liefers GJ, van de Velde CJ, Kuppen PJ (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16:1272–1280PubMedCrossRef
42.
Zurück zum Zitat Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B (2007) Metronomic cyclophoshamide regimen selectively depletes CD4 + CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648PubMedCrossRef Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B (2007) Metronomic cyclophoshamide regimen selectively depletes CD4 + CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648PubMedCrossRef
43.
Zurück zum Zitat Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689–3697PubMed Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689–3697PubMed
44.
Zurück zum Zitat Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H (2008) CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 122:2286–2293PubMedCrossRef Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H (2008) CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 122:2286–2293PubMedCrossRef
45.
Zurück zum Zitat Caudle AS, Yu T, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA (2012) Local–regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14:R83PubMedCrossRef Caudle AS, Yu T, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA (2012) Local–regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14:R83PubMedCrossRef
46.
Zurück zum Zitat Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobágyi GN, Gonzalez-Angulo AM (2008) Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13:6–15PubMedCrossRef Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobágyi GN, Gonzalez-Angulo AM (2008) Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13:6–15PubMedCrossRef
47.
Zurück zum Zitat Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027PubMedCrossRef Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027PubMedCrossRef
48.
Zurück zum Zitat Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746PubMed Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746PubMed
Metadaten
Titel
Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs
verfasst von
Lutfiye Demir
Seyran Yigit
Hulya Ellidokuz
Cigdem Erten
Isil Somali
Yuksel Kucukzeybek
Ahmet Alacacioglu
Suna Cokmert
Alper Can
Murat Akyol
Ahmet Dirican
Vedat Bayoglu
Aysegul Akder Sari
Mustafa Oktay Tarhan
Publikationsdatum
01.12.2013
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 8/2013
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-013-9602-9

Weitere Artikel der Ausgabe 8/2013

Clinical & Experimental Metastasis 8/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.